Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biomet To Settle With DOJ, SEC On Bribery Charges For $22.7Mln

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/26/2012 | 05:50pm CEST

Medical-device company Biomet Inc. has agreed to pay about $22.7 million to settle civil and criminal charges stemming from allegations the company's units and agents bribed public doctors in Argentina, Brazil and China for nearly a decade to win business, the Department of Justice and the Securities and Exchange Commission said Monday.

The agencies allege that Biomet and its four units paid bribes from 2000 to August 2008, and employees and managers at all levels of the parent company and the units were involved, along with distributors. Biomet's compliance and internal audit functions failed to stop the payments to doctors even after learning about the illegal practices, the agencies alleged.

A Biomet representative wasn't immediately available for comment.

Biomet agreed to pay a $17.3 million criminal penalty for allegedly violating the Foreign Corrupt Practices Act. In its Justice Department agreement, it is required to implement rigorous internal controls, cooperate fully with the Justice Department and retain a compliance monitor for 18 months. Additionally, the company will pay $5.4 million in disgorgement of profits and prejudgment interest, as part of its separate SEC settlement.

Biomet, a privately held company that sells products used by orthopedic surgeons, is the third medical device firm to enter into a settlement with government agencies as part of the SEC and Justice Department's ongoing global investigation into medical-device companies allegedly bribing publicly employed physicians. Previously, Johnson & Johnson (>> Johnson & Johnson) and Smith & Nephew PLC (SNN, SN.LN) agreed to pay criminal penalties and entered into deferred prosecution agreements related to similar investigations, the Justice Department said.

In January, Biomet said its fiscal second-quarter loss widened as a drop in spine and bone-healing sales as well as higher costs masked the company's revenue growth.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; [email protected]

Stocks mentioned in the article : Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10:39a JOHNSON & JOHNSON : scores $260M+ DOD orthopedics contract
04/28 JOHNSON & JOHNSON : Janssen Research & Development Submits Supplemental New Drug..
04/28 JOHNSON & JOHNSON : How Johnson & Johnson Is Leading When It Comes to Military L..
04/28 ACTELION : Publication of the definitive notice of the end result of Actelion te..
04/28 JOHNSON & JOHNSON : European Commission Extends Approval for Janssen’s DAR..
04/28 JOHNSON & JOHNSON : Sharon Kleyne & Neville L. Johnson Explore Privacy & Bullies..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 DAILY DIVIDEND REPORT : Xom, jnj, su, xlnx, pfe, cvx, ko
04/27 JOHNSON & JOHNSON : Dr. Yolanda Chong Joins Recursion Pharmaceuticals to Advance..
04/27 JOHNSON & JOHNSON : Announces Dividend Increase of 5.0%
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 JOHNSON & JOHNSON : 55 Years Of Increasing Dividends, A Company For All Seasons
04/28 HOW TO POSITION YOUR PORTFOLIO FOR T : 3 Actionable Steps
04/28 How Low Can You Go? U.S. Pharma Already Shoulders Light Tax Burden
04/28 Calling All Heart Docs - Your Diabetes Drugs Need You
04/28 Johnson & Johnson (JNJ) Investor Presentation - Slideshow
Advertisement
Financials ($)
Sales 2017 75 666 M
EBIT 2017 23 472 M
Net income 2017 17 913 M
Debt 2017 8 242 M
Yield 2017 2,73%
P/E ratio 2017 18,82
P/E ratio 2018 16,91
EV / Sales 2017 4,53x
EV / Sales 2018 4,33x
Capitalization 334 714 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 129 $
Spread / Average Target 4,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
SANOFI11.79%121 897
More Results